Abstract
BackgroundFew studies have assessed mantle cell lymphoma (MCL) incidence trends in the U.S. National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) areas. Previous studies were 5 to 9 years old and MCL incidence in Texas remains unknown. This study updated the temporal trends and variations of MCL incidence in the SEER areas and compared them with counterpart data in Texas.ResultsFrom 1995 to 2013, there were 2, 435 and 5, 193 newly diagnosed MCL patients in Texas and SEER areas. Age-adjusted MCL incidence was 0.91 per 100,000 persons per year in Texas and 1.01 in SEER areas. MCL incidence increased steadily with an annual percent change (APC) of 2.56% in SEER areas and an APC of 2.16% in Texas. In SEER areas, APCs for MCL incidence were significantly different from zero in patients with advanced stage tumor (3.33%), male (2.71%), elderly patients ≥ 80 years old (4.21%) and non-Hispanic white patients (2.83%) (all P < 0.05). Similar patterns were found in Texas for both incidence rates and APCs.Materials and methodsWe identified all adult patients with newly diagnosed MCL in Texas Cancer Registry and SEER databases from 1995 to 2013. Age-adjusted incidence rates were calculated and negative binomial regression model was used to assess the factors associated with MCL incidence.ConclusionsMCL incidence rates increased over time in both Texas and SEER areas, with increases being greater in male, non-Hispanic white, and elderly patient ≥70 years with advanced stage tumors. Texas has similar MCL incidence trends and disparities as the national SEER areas.
Highlights
Non-Hodgkin lymphoma (NHL) is the seventh most common cancer and eighth leading cause of cancer death in the U.S [1]
mantle cell lymphoma (MCL) incidence rates increased over time in both Texas and SEER areas, with increases being greater in male, non-Hispanic white, and elderly patient ≥70 years with advanced stage tumors
We found that in SEER areas, elderly males had the highest MCL incidence rates (IRs) among all subgroups with high MCL incidence (70–79 years, Incidence rates (IR): 6.24, 95% CI: 5.86–6.63; 80+ years, IR: 7.22, 95% CI: 6.66–7.81), indicating that substantial www.impactjournals.com/oncotarget
Summary
Non-Hodgkin lymphoma (NHL) is the seventh most common cancer and eighth leading cause of cancer death in the U.S [1]. Mantle cell lymphoma (MCL) is a rare, aggressive subtype of B-cell NHL, affecting 3% to 6% of patients with NHL [3, 4]. Epidemiology and End Results (SEER) areas showed that MCL incidence has increased steadily from 1992 [3, 6] when it was established as a distinct type of lymphoma [7]. In Texas, MCL incidence and disease characteristics remain unexplored and the data were not released until 1995. Few studies have assessed mantle cell lymphoma (MCL) incidence trends in the U.S National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) areas. Previous studies were 5 to 9 years old and MCL incidence in Texas remains unknown.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
